UniPharma Co., Ltd. (6621.TWO)

TWD 13.85

(-0.72%)

Market Cap (In TWD)

491.68 Million

Revenue (In TWD)

103.22 Million

Net Income (In TWD)

-21.81 Million

Avg. Volume

100.66 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
11.8-19.65
PE
-
EPS
-
Beta Value
0.626
ISIN
TW0006621006
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Yu-Shan Wang Ph.D.
Employee Count
-
Website
https://www.uni-pharma.com
Ipo Date
2017-08-18
Details
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. The company provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. It offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was incorporated in 1998 and is based in Taipei, Taiwan.